treprostinil tillomed 10mg/ml infuzní roztok
tillomed pharma gmbh, schönefeld array - 16773 treprostinil - infuzní roztok - 10mg/ml - treprostinil
treprostinil tillomed 2,5mg/ml infuzní roztok
tillomed pharma gmbh, schönefeld array - 16773 treprostinil - infuzní roztok - 2,5mg/ml - treprostinil
treprostinil tillomed 5mg/ml infuzní roztok
tillomed pharma gmbh, schönefeld array - 16773 treprostinil - infuzní roztok - 5mg/ml - treprostinil
voriconazole fresenius kabi 200mg prášek pro infuzní roztok
fresenius kabi s.r.o., praha array - 14426 vorikonazol - prášek pro infuzní roztok - 200mg - vorikonazol
carprodyl f 50.0 mg tableta
ceva animal health slovakia s.r.o. - karprofen - tableta - deriváty kyseliny propionové - psi
adempas
bayer ag - riociguat - hypertenze, plicní - antihypertenzíva pro plicní arteriální hypertenzi - chronic thromboembolic pulmonary hypertension (cteph)adempas is indicated for the treatment of adult patients with who functional class (fc) ii to iii withinoperable cteph,persistent or recurrent cteph after surgical treatment,to improve exercise capacity. pulmonary arterial hypertension (pah)adultsadempas, as monotherapy or in combination with endothelin receptor antagonists, is indicated for the treatment of adult patients with pulmonary arterial hypertension (pah) with who functional class (fc) ii to iii to improve exercise capacity. Účinnost byla prokázána v pau populace, včetně etiologie idiopatické nebo dědičné pah nebo pah spojenou s onemocněním pojivové tkáně. paediatricsadempas is indicated for the treatment of pah in paediatric patients aged less than 18 years of age and body weight ≥ 50 kg with who functional class (fc) ii to iii in combination with endothelin receptor antagonists.
atosiban sun
sun pharmaceutical industries europe b.v. - atosiban (as acetate) - předčasné narození - další gynecologicals - atosiban je uvedeno oddálit hrozící předčasný porod u těhotných dospělých žen s:pravidelné kontrakce dělohy nejméně 30 vteřin ve výši ≥ 4 za 30 minut;cervikální dilatace 1 až 3 cm (0-3 pro nulliparas) a zahlazení ≥ 50%;gestační věk od 24 do 33 ukončených týdnů;normální fetální srdeční frekvence.
aftovaxpur doe
boehringer ingelheim vetmedica gmbh - maximum three of the following purified, inactivated foot-and-mouth disease virus strains: o1 manisa ≥ 6 pd50*; o1 bfs ≥ 6 pd50*; o taiwan 3/97 ≥ 6 pd50*; a22 iraq ≥ 6 pd50*; a24 cruzeiro ≥ 6 pd50*; a turkey 14/98 ≥ 6 pd50*; asia 1 shamir ≥ 6 pd50*; sat2 saudi arabia ≥ 6 pd50*; * pd50 – 50% protective dose in cattle as described in ph. eur. monograph 0063. - imunologická léčba - pigs; cattle; sheep - aktivní imunizace skotu, ovcí a prasat ve věku 2 týdnů proti slintavce a kulhavce ke snížení klinických příznaků.
iasibon
pharmathen s.a. - kyselina ibandronová - hypercalcemia; fractures, bone; neoplasm metastasis; breast neoplasms - léky na léčbu nemocí kostí - concentrate for solution for infusion prevention of skeletal events (pathological fractures, bone complications requiring radiotherapy or surgery) in patients with breast cancer and bone metastases. léčba hyperkalcémie vyvolané nádorem s výskytem nebo bez výskytu metastáz. film-coated tablets prevention of skeletal events (pathological fractures, bone complications requiring radiotherapy or surgery) in patients with breast cancer and bone metastases.
virbagen omega
virbac s.a. - recombinant omega interferon of feline origin - immunostimulants, - dogs; cats - dogsreduction of mortality and clinical signs of parvovirosis (enteric form) in dogs from one month of age. catstreatment of cats infected with feline leukaemia virus (felv) and / or feline immunodeficiency virus (fiv), in non-terminal clinical stages, from the age of nine weeks. in a field study conducted, it was observed that there was:a reduction of clinical signs during the symptomatic phase (four months);a reduction of mortality:in anaemic cats, mortality rate of about 60% at four, six, nine and 12 months was reduced by approximately 30% following treatment with interferon;in non-anaemic cats, mortality rate of 50% in cats infected by felv was reduced by 20% following treatment with interferon. in cats infected by fiv, mortality was low (5%) and was not influenced by the treatment.